RecruitingNot ApplicableNCT07552922

Determining INdividual Preferences for Gynecomastia avOidance (DINGO) - Stage 1

Determining INdividual Preferences for Gynecomastia avOidance (DINGO) - Qualitative Stage


Sponsor

St Vincent's Hospital, Sydney

Enrollment

24 participants

Start Date

Dec 1, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

This study aims to explore the perceptions of men with prostate cancer (PCa) and high-risk biochemical recurrence (BCR) regarding the risk of breast-related side effects, including gynaecomastia, from treatment.


Eligibility

Sex: MALEMin Age: 18 Years

Inclusion Criteria2

  • Men with high-risk BCR PCa but no ADT+/-ARPI experience.
  • Men with ADT+/-ARPI experience who have experienced breast-related side effects from this treatment.

Exclusion Criteria1

  • Men receiving psychiatric care as a consequence of their prostate cancer diagnosis or treatment thereof.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERSemi-structured Interview

this t study will use qualitative methods to explore men's views of gynaecomastia from high-risk BCR PCa treatments (Stage 1) to inform attributes and levels for a later DCE to examine patient treatment preferences (Stage 2).


Locations(1)

Kinghorn Cancer Centre

Sydney, New South Wales, Australia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07552922


Related Trials